Skip to content

Omega-3 trials in intensive care reported benefits, but mortality findings differed

A review of randomized trials reported improvements in several inflammatory and clinical outcomes, while deaths during intensive care did not show a clear reduction.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Supplementation was reported to reduce several inflammatory markers, some complications and length of intensive-care stay. The review also reported lower 28-day mortality, while mortality during intensive care did not clearly differ. These findings concern critically ill patients receiving hospital care and do not establish benefits from routine supplementation in other populations.

Keep in mind

The abstract provides no effect sizes, confidence intervals, control-treatment details or supplementation protocols. It therefore cannot show the magnitude or precision of the reported benefits or identify which regimens produced them.

The review covered different kinds of outcomes

The trials tested omega-3 supplements in intensive-care patients. Reported outcomes included blood markers, organ-failure scores, infections and survival, so changes in inflammation should be considered separately from changes in patients' clinical course.

Mortality depended on the endpoint

Deaths during intensive care and deaths assessed at a fixed follow-up point are distinct outcomes. The different findings should both remain visible; the nonsignificant intensive-care mortality result does not prove that treatments were equivalent.

CHECK THE ORIGINAL

The original publication

Effects of omega-3 fatty acids on hyper-inflammatory response and clinical outcomes in critically ill patients: a meta-analysis.

Liu T, Wang X, Wang XH et al.
Intensive Crit Care Nurs · 2026

PubMed ID
40974763
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.